Geetanjali Pharmaceuticals (India) P. Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 26-06-2024
- Paid Up Capital ₹ 0.27 M
as on 26-06-2024
- Company Age 35 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 19.37%
(FY 2022)
- Profit -50.09%
(FY 2022)
- Ebitda -39.50%
(FY 2022)
- Net Worth 1.64%
(FY 2022)
- Total Assets 1.41%
(FY 2022)
About Geetanjali Pharmaceuticals (India) P.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.27 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Nimbalkar, Kaustubh Nimbalkar, Sushmita Nimbalkar, and One other member serve as directors at the Company.
- CIN/LLPIN
U99999MH1989PTC053485
- Company No.
053485
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Sep 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Geetanjali Pharmaceuticals (India) P.?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Nimbalkar  | Managing Director | 19-Sep-1989 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kaustubh Nimbalkar | Director | 05-Jul-2008 | Current |
| Sushmita Nimbalkar | Director | 16-Jun-2008 | Current |
| Jayashree Nimbalkar | Director | 16-Jun-2008 | Current |
Financial Performance and Corporate Structure Insights of Geetanjali Pharmaceuticals (India) P..
Geetanjali Pharmaceuticals (India) P. Ltd., for the financial year ended 2022, experienced significant growth in revenue, with a 19.37% increase. The company also saw a substantial fall in profitability, with a 50.09% decrease in profit. The company's net worth moved up by a moderate rise of 1.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Geetanjali Pharmaceuticals (India) P.?
In 2021, Geetanjali Pharmaceuticals (India) P. had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Geetanjali Pharmaceuticals (India) P.?
Unlock and access historical data on people associated with Geetanjali Pharmaceuticals (India) P., such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geetanjali Pharmaceuticals (India) P., offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geetanjali Pharmaceuticals (India) P.'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
